Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Journal
Advances in therapy
Journal Volume
39
Journal Issue
6
Pages
2641
Date Issued
2022-06
Author(s)
Ahn, Hanjong
Han, Weiqing
Huang, Shu-Pin
Wu, Hsi-Chin
Ma, Lulin
Yamada, Shunsuke
Suga, Kazutaka
Xie, Li-Ping
Abstract
Enzalutamide significantly improved clinical outcomes compared with placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) with disease progression despite androgen deprivation therapy (ADT) in the PREVAIL study. However, few patients from Asia were enrolled. Our study (NCT02294461) aimed to evaluate the safety and efficacy of enzalutamide in this disease setting in patients in mainland China, Korea, Taiwan, and Hong Kong.
Subjects
Asia; Castration-resistant prostate cancer; Enzalutamide; Metastasis; Treatment efficacy
SDGs
Publisher
SPRINGER
Type
journal article